PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15177499-1 2004 Halofuginone, a widely used alkaloid coccidiostat, is a potent inhibitor of collagen alpha 1 (I) and matrix metalloproteinase 2 gene expression. halofuginone 0-12 matrix metallopeptidase 2 Mus musculus 101-127 26099922-1 2015 BACKGROUND: Halofuginone (HF) is a low-molecular-weight alkaloid that has been demonstrated to interfere with Metalloproteinase-2 (MMP-2) and Tumor Growth Factor-beta (TGF-beta) function and, to present antiangiogenic, antiproliferative and proapoptotic properties in several solid tumor models. halofuginone 12-24 matrix metallopeptidase 2 Mus musculus 131-136 11099465-1 2000 We have previously demonstrated that halofuginone, a low molecular weight quinazolinone alkaloid, is a potent inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 (MMP-2) gene expression. halofuginone 37-49 matrix metallopeptidase 2 Mus musculus 146-172 11099465-1 2000 We have previously demonstrated that halofuginone, a low molecular weight quinazolinone alkaloid, is a potent inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 (MMP-2) gene expression. halofuginone 37-49 matrix metallopeptidase 2 Mus musculus 174-179 10463616-1 1999 We have previously demonstrated that halofuginone, a widely used alkaloid coccidiostat, is a potent inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 gene expression. halofuginone 37-49 matrix metallopeptidase 2 Mus musculus 136-162 10473075-0 1999 Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone. halofuginone 88-100 matrix metallopeptidase 2 Mus musculus 14-40 10473075-5 1999 We now report that expression of the MMP-2 gene by murine (MBT2-t50) and human (5637) bladder carcinoma cells is highly susceptible to inhibition by halofuginone. halofuginone 149-161 matrix metallopeptidase 2 Mus musculus 37-42 10473075-7 1999 This inhibition is due to an effect of halofuginone on the activity of the MMP-2 promoter, as indicated by a pronounced suppression of chloramphenicol acetyltransferase activity driven by the MMP-2 promoter in transfected MBT2 cells. halofuginone 39-51 matrix metallopeptidase 2 Mus musculus 75-80 10473075-7 1999 This inhibition is due to an effect of halofuginone on the activity of the MMP-2 promoter, as indicated by a pronounced suppression of chloramphenicol acetyltransferase activity driven by the MMP-2 promoter in transfected MBT2 cells. halofuginone 39-51 matrix metallopeptidase 2 Mus musculus 192-197 10473075-9 1999 Halofuginone-treated cells failed to invade through reconstituted basement-membrane (Matrigel) coated filters, in accordance with the inhibition of MMP-2 gene expression. halofuginone 0-12 matrix metallopeptidase 2 Mus musculus 148-153 10473075-13 1999 These results indicate that the potent antimetastatic activity of halofuginone is due primarily to a transcriptional suppression of the MMP-2 gene, which results in a decreased enzymatic activity, matrix degradation, and tumor cell extravasation. halofuginone 66-78 matrix metallopeptidase 2 Mus musculus 136-141